RU94032103A - PEPTIDES, PHARMACEUTICAL COMPOSITION, VACCINE, CONJUGAT, TREATMENT METHODS AND IDENTIFICATION - Google Patents

PEPTIDES, PHARMACEUTICAL COMPOSITION, VACCINE, CONJUGAT, TREATMENT METHODS AND IDENTIFICATION

Info

Publication number
RU94032103A
RU94032103A RU94032103/04A RU94032103A RU94032103A RU 94032103 A RU94032103 A RU 94032103A RU 94032103/04 A RU94032103/04 A RU 94032103/04A RU 94032103 A RU94032103 A RU 94032103A RU 94032103 A RU94032103 A RU 94032103A
Authority
RU
Russia
Prior art keywords
peptides
nvu
conjugat
vaccine
identification
Prior art date
Application number
RU94032103/04A
Other languages
Russian (ru)
Inventor
В. Чизари Фрэнсис
Феррари Карло
Пенна Амалиа
Original Assignee
Дзе Скриппс Рисерч Инститьют
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Дзе Скриппс Рисерч Инститьют filed Critical Дзе Скриппс Рисерч Инститьют
Publication of RU94032103A publication Critical patent/RU94032103A/en

Links

Claims (1)

Пептиды используют для определения эпитопов, которые стимулируют НZА-ограниченную, цитотоксическую Т-лимфоцитную активность против антигенов вируса гепатита В. Эти пептиды получают из участков НВУ нуклеокапсида, оболочки, полимеразы и транскрипционного трансактиваторного Х протеина, и они особенно пригодны для лечения или предотвращения НВУ инфекции, включая способы стимуляции иммунной реакции хронически инфицированных индивидуумов в ответ на НВУ антигены. Фармацевтические композиции и вакцины против гепатита В, которые включают пептиды и физиологически приемлемые носители, можно использовать вместе в другими НВУ вакцинами для создания более эффективного иммунитета против этой болезни. Представлены способы идентификации индивидуумов, которые особенно предрасположены к развитию хронической НВУ инфекции, и которых можно лечить CTZ пептидами.Peptides are used to determine epitopes that stimulate HZA-limited, cytotoxic T-lymphocyte activity against hepatitis B antigens. These peptides are obtained from the NVU sections of the nucleocapsid, envelope, polymerase, and transcriptional X protein, and they are especially suitable for treating or preventing the NVU infection , including ways to stimulate the immune response of chronically infected individuals in response to NVU antigens. Pharmaceutical compositions and hepatitis B vaccines, which include peptides and physiologically acceptable carriers, can be used together with other NVU vaccines to create more effective immunity against this disease. Presents methods for identifying individuals who are particularly prone to developing chronic NWU infection and who can be treated with CTZ peptides.
RU94032103/04A 1991-08-26 1992-08-26 PEPTIDES, PHARMACEUTICAL COMPOSITION, VACCINE, CONJUGAT, TREATMENT METHODS AND IDENTIFICATION RU94032103A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US749540 2007-05-16

Publications (1)

Publication Number Publication Date
RU94032103A true RU94032103A (en) 1995-09-27

Family

ID=

Similar Documents

Publication Publication Date Title
BG98522A (en) Peptides including cytotoxic t-lymphocytic response to the virus of hepatite b
CY1106152T1 (en) NEW ANTI-HIV IMMUNE (ANTITOXINS), PREPARATION METHODS AND APPLICATION IN THE PREVENTION AND TREATMENT OF AIDS
EP0726758A4 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
GB2255093A (en) Hiv-1 core protein fragments
Herrington et al. Safety and immunogenicity of a recombinant sporozoite malaria vaccine against Plasmodium vivax
DE69433007D1 (en) PEPTIDES FOR INDUCING A RESPONSE OF THE CYTOTOXIC T-LYMPHOCYTES AGAINST THE HEPATITIS B VIRUS
Marchou et al. A 3-week hepatitis B vaccination schedule provides rapid and persistent protective immunity: a multicenter, randomized trial comparing accelerated and classic vaccination schedules
Mifune et al. Essential role of T cells in the postexposure prophylaxis of rabies in mice
Houston et al. Adjuvant effects of diethylaminoethyl-dextran
Fujibayashi et al. Production of interferon by immune lymphocytes exposed to herpes simplex virus-antibody complexes
Lin et al. A new immunostimulatory complex (PICKCa) in experimental rabies: antiviral and adjuvant effects
RU94032103A (en) PEPTIDES, PHARMACEUTICAL COMPOSITION, VACCINE, CONJUGAT, TREATMENT METHODS AND IDENTIFICATION
RU93053037A (en) VACCINE AGAINST THE DISEASE OF THE BIRDS BAG AND TREATMENT METHODS
Willey et al. Herpes simplex virus type 1-vaccinia virus recombinant expressing glycoprotein B: protection from acute and latent infection
FI93423B (en) Procedure for the preparation of vaccine
RU94038427A (en) Peptides, conjugates, pharmaceutical compositions, treatment methods, identification method
MC2306A1 (en) PEPTIDES BLOCKING HUMAN IMMUNODEFICIENCY VIRUS INFECTIONS AND METHODS OF USE
Zourbas et al. Immunization of dental surgeons against hepatitis B virus infection.
Thomson IMMUNOLOGICAL AND PROTECTIVE RESPONSES TO A HERPES SIMPLEX VIRUS SUBUNIT VACCINE IN A LABIAL INFECTION MODEL IN MICE.
Mukerjee et al. Effect of adjuvants on immunization with dengue virus-induced cytotoxic factor
Georgadze et al. Development and testing of antistaphylococcal heterogenous gamma globulin.
FR2792639B1 (en) NOVEL ANTI-HIV IMMUNOGENES (TOXOIDS), NOVEL PREPARATION METHODS AND APPLICATION FOR THE PREVENTION AND TREATMENT OF AIDS
CA2156416A1 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
Brangier The French Experience With Hepatitis B Vaccine.